Introduction – National prevalence surveys (NPS) of healthcare-associated infections and antimicrobial treatments in healthcare facilities (HCFs) were conducted in 2017 and 2022 in France. The objective of this article is to describe, in a secondary analysis, antifungal (AF) treatments and nosocomial fungal infections (NFIs) observed in 2022, as well as their trends compared to 2017.Method – The 2017 and 2022 ENPs were conducted on a specific day between May 15 and June 30, including patients with short-, medium-, and long-term stays at participating HCFs (i.e., 151,676 patients in 2022 versus 80,898 in 2017). Prevalence estimates in the population of hospitalized patients in France are reported per 100 patients with a 95% confidence interval. The analyses account for a sampling design. Results – In 2022, the prevalence of AF treatments is estimated at 1.05 [0.93–1.16] per 100 patients, a significant increase compared to 2017 (0.78 [0.64–0.92]). The highest prevalences are in hematology and intensive care. The most commonly prescribed antifungals for curative treatment are fluconazole, amphotericin B, and caspofungin; for prophylaxis, they are posaconazole, amphotericin B, and fluconazole. The prevalence of patients with at least one antifungal infection (AFI) is 0.23 [0.19–0.27] in 2022 versus 0.14 [0.10–0.18] in 2017, representing a 64% increase. Candida albicans is the most common species. Conclusion – Given the increasing prevalence of antifungal treatments, it is essential to continue efforts to promote appropriate use, particularly by implementing coordinated multidisciplinary initiatives that contribute to the quality of care.